XNK Therapeutics enters into agreement with US-based biotechnology company
XNK Therapeutics AB (“XNK”) today announced that the company has entered into an agreement with a US biotechnology company. Under the agreement the parties will perform preclinical evaluation of XNK’s autologous NK cell therapy candidate XNK02 in combination with a drug candidate currently in clinical development by the US company. The combination will initially be tested against acute myeloid leukemia (AML). The collaboration supplements XNK’s current collaborations in the field of AML with the University of Texas MD Anderson Cancer Center. For more information, please contact: